Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Cancer Trial Hopes to Find New Patient Populations That Will Respond to Already-Approved Drugs

May 19th 2022

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Kidney Cancer Nurse Is an Icon in Her Field

May 8th 2022

Laura Wood, M.S.N., RN, OCN, has "skill, dedication, boundless compassion and drive to improve the lives of those affected by kidney cancer."

Unmet Needs and Future Perspectives in the Treatment of RCC

May 5th 2022

Bryan Lewis, president of KidneyCAN, and Chung-Han Lee, MD, describe unmet needs and future perspectives in the treatment of renal cell carcinoma.

The Importance of Patients Advocating for Themselves During Their RCC Journey

May 5th 2022

Meryl Uranga describes her path with metastatic clear cell renal cell carcinoma after first treatment, and how it has affected her outlook on her life and future.

Quality-of-Life with Systemic Therapies in Metastatic Clear Cell RCC

May 5th 2022

A look at how to consider quality-of-life clinical trial and patient-reported data when treating clear cell renal cell carcinoma with combination therapies.

Nurse Helps Patients Through Education and Cancer Care Protocols

May 4th 2022

Christine Amoroso, B.S.N., RN, OCN, figured out the best way to deliver direct-to-kidney treatment for her patients.

Patient Experience with Systemic Therapy-Related Toxicities in Metastatic RCC

May 2nd 2022

Meryl Uranga describes her personal experience with managing the side effects of treatment for clear cell renal cell carcinoma.

Adverse Events Associated with IO-TKI Therapies in Metastatic Clear Cell RCC

May 2nd 2022

An overview of side effects commonly seen with lenvatinib plus pembrolizumab for the treatment of clear cell renal cell carcinoma.

Educated Patient® Kidney Cancer Summit Combination Therapy Panel: April 9, 2022

May 1st 2022

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI-Related Side Effects Presentation: April 9, 2022

April 30th 2022

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/TKI Therapies Presentation: April 9, 2022

April 29th 2022

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit IO/IO Therapies Presentation: April 9, 2022

April 28th 2022

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Communicating With Providers About Immunotherapy/TKI Combo Treatment: April 9, 2022

April 27th 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss communicating with a care team about treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Side Effects from Immunotherapy/TKI Combo Treatment: April 9, 2022

April 26th 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss side effects and dose reductions after treatment with immunotherapy combined with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Panel on Immunotherapy/TKI Combo Treatment: April 9, 2022

April 25th 2022

Watch Dr. Thomas Hutson, Louise Gunter and Meryl Uranga discuss the treatment of combining immunotherapy with tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Frontline Therapy Panel: April 9, 2022

April 24th 2022

Watch Dr. Thomas Hutson, Dr. Jose Karam, Dr, Naomi Haas, and Kiran Kehoe answer questions about frontline therapy during the CURE Educated Patient Kidney Cancer Summit.

Educated Patient® Kidney Cancer Summit Adjuvant Therapy Options Presentation: April 9, 2022

April 23rd 2022

Watch Dr. Naomi Haas, from Abramson Cancer Center, discuss adjuvant therapy options, during the CURE Educated Patient Kidney Cancer Summit.

More Research Efforts Needed to Ensure Kidney Cancer Treatments ‘Get Smarter’ to Limit Side Effects, Expert Says

April 22nd 2022

An expert discusses the side effects patients with kidney cancer may experience from immunotherapy and tyrosine kinase inhibitor treatment, and how more research is needed in to ensure patients experience less side effects.

Educated Patient® Kidney Cancer Summit Surgical Options Presentation: April 9, 2022

April 22nd 2022

Watch Dr. Jose Karam, from The University of Texas MD Anderson Cancer Center, discuss surgical options, during the CURE Educated Patient Kidney Cancer Summit.

Role of Nurses in the Multidisciplinary Management of RCC

April 21st 2022

Clinical nurse Kiran Virdee explains why a multidisciplinary treatment approach to clear cell renal cell carcinoma is beneficial.

Factors for Consideration in RCC Treatment Decision-Making

April 21st 2022

An oncologist describes the necessity of discussing options with a patient when picking a treatment approach for clear cell renal cell carcinoma.

Educated Patient® Kidney Cancer Summit Diagnosis Panel: April 9, 2022

April 21st 2022

Watch Dr. Vitaly Margulis, Dr. Rana Mckay and Kwame Garrett-Price answer questions about kidney cancer diagnoses during the CURE Educated Patient Kidney Cancer Summit.

How a Standardized Staging System Helps Patients, Providers Choose Best Kidney Cancer Treatment Options

April 20th 2022

By understanding what a TNM staging score is, patients and clinicians can determine the best line of treatment for their kidney cancer, as well as what the survivorship care plan should be.

Educated Patient® Kidney Cancer Summit Genetic Testing in RCC Presentation: April 9, 2022

April 20th 2022

Watch Dr. Rana R. McKay, from the University of California San Diego, discuss genetic testing in renal cell carcinoma during the CURE Educated Patient Kidney Cancer Summit.

Clinical Trials Come to a ‘Disappointing’ End When Drug Combo Fails to Improve Outcomes in Kidney and Bladder Cancer

April 19th 2022

The clinical development of BEMPEG plus Opdivo will end after clinical trials showed that the drug combination did not lead to significant improvements in outcomes in patients with kidney or bladder cancer.

Lenvatinib + Pembrolizumab for the Treatment of Metastatic Clear Cell RCC

April 19th 2022

A review of clinical trial data on combination treatments for clear cell renal cell carcinoma.

A Patient’s Perspective on Choosing Systemic Therapy for Metastatic RCC

April 19th 2022

Patients with clear cell renal cell carcinoma speak to their experiences with systemic treatments.

Educated Patient® Kidney Cancer Summit Staging Presentation: April 9, 2022

April 19th 2022

Watch Dr. Vitaly Margulis, from UT Southwestern Medical Center, discuss staging, during the CURE Educated Patient Kidney Cancer Summit.

‘Today Show’ Anchor Hoda Kotb Discusses Fertility Issues Following Cancer Diagnosis, Pfizer Pulls Blood Pressure Drugs Due to Cancer Concerns and More

March 25th 2022

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

Novel Drug-Keytruda Combo Meets Goal for Kidney Cancer Outcomes Before Trial Enrollment Ends

March 24th 2022

MRX0518 plus Keytruda led to a clinical benefit in four out of 16 evaluable patients with renal cell carcinoma. The drug duo will continue to be studied for multiple types of solid tumors.